863504-75-0

Basic information

• Product Name: 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoic acid
• Synonyms: 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoic acid
• CAS NO: 863504-75-0
• Molecular Weight: 380.419
• Mol File: 863504-75-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoic acid(863504-75-0)
• EPA Substance Registry System: 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoic acid(863504-75-0)

Safety Data

• Hazardous Substances Data: 863504-75-0(Hazardous Substances Data)

Upstream product

• 149104-88-1 4-methanesulphonylphenylboronic acid 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 863504-77-2 3-hydroxy-5-((S)-2-methoxy-1-methyl-ethoxy)-benzoic acid methyl ester 
• 851885-42-2 methyl 3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]benzoate 
• 863504-76-1 methyl 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoate 

Downstream Products

• 1001419-60-8 C₁₈H₁₉ClO₆S 
• 1107062-16-7 C₂₅H₂₇NO₇S 
• 1093121-32-4 C₂₉H₂₅F₃N₂O₉S₂ 
• 1093121-00-6 C₂₈H₂₃F₃N₂O₉S₂ 
• 1093121-02-8 C₃₁H₃₅N₂O₁₀PS₂ 
• 1093121-13-1 C₂₇H₂₆N₂O₈S₂ 
• 1093121-36-8 C₄₅H₄₄N₂O₁₄S₃ 
• 1093120-72-9 C₂₈H₂₅N₃O₇S₂ 
• 1093120-81-0 C₂₆H₂₄FN₃O₇S₂ 
• 1093121-34-6 C₂₈H₂₇N₃O₉S₂ 
• 1093121-26-6 C₂₉H₂₈N₂O₉S₂ 

Relevant articles and documents

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS

Compounds of Formula (I), wherein R1- R10, A and X1 to X3 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.